Every 8-K that CRISPR Therapeutics AG (CRSP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CRSP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRSP filings page.
CRISPR Therapeutics reported second quarter 2026 results, highlighted by rapid commercial progress for CASGEVY. CASGEVY generated $76 million in revenue, up 78% sequentially and 151% year over year, and is approved in 39 countries. The FDA expanded its label to children 2 years and older with sickle cell disease or transfusion‑dependent beta thalassemia, potentially enabling treatment for about 5,500 additional patients, while Vertex secured reimbursement in Germany for eligible patients 12 and older.
Beyond CASGEVY, the company advanced a broad gene‑editing portfolio, including Phase 1 trials for CTX340 in refractory hypertension and CTX460 in alpha‑1 antitrypsin deficiency, ongoing CTX310 liver programs, siRNA candidate CTX611 in Phase 2, and allogeneic CAR‑T zugo‑cel in multiple autoimmune and oncology indications. Cash, cash equivalents and marketable securities totaled $2,364.4 million as of June 30, 2026, supported by $585.4 million of convertible senior note proceeds in March. Second‑quarter R&D expense was $67.2 million, collaboration expense $40.3 million, and net loss narrowed to $91.2 million from $208.5 million a year earlier.
CRISPR Therapeutics reported the results of its June 4, 2026 annual shareholder meeting, where all management proposals were approved. Shareholders adopted the new 2026 Stock Option and Incentive Plan, which replaces and rolls forward remaining capacity from earlier equity plans.
They also approved amendments to the company’s Swiss articles of association, including an increase to the capital band and an increase to conditional share capital for potential conversion of bonds and similar instruments. The meeting re-elected all eleven directors, four Compensation Committee members, the independent voting rights representative, and Ernst & Young entities as Swiss statutory auditor and U.S. registered public accounting firm.
Shareholders approved the 2025 financial statements, carried forward the net loss, discharged the Board and Executive Committee from liability for 2025 activities, and backed both Swiss and U.S.-style executive compensation votes, including multiple binding decisions on director and executive pay and equity grants.
CRISPR Therapeutics reported first quarter 2026 results that combine early commercial revenue from CASGEVY with a still-sizeable net loss and a much stronger cash position.
CASGEVY, its gene-edited therapy for sickle cell disease and transfusion-dependent beta thalassemia, generated $43 million in first quarter 2026 revenue. More than 500 people worldwide have initiated treatment, and regulators have approved CASGEVY in multiple regions covering over 60,000 eligible patients. Vertex has completed a U.S. regulatory submission to extend use to children ages 5–11, and reimbursement continues to expand in key markets.
Financially, cash, cash equivalents and marketable securities were $2.44 billion as of March 31, 2026, up from $1.98 billion at year-end, mainly from $585.4 million in net proceeds from convertible senior notes. Research and development expenses were $68.6 million, and general and administrative expenses were $17.2 million, both lower than a year earlier. Net loss narrowed to $122.9 million (basic and diluted net loss per share of $1.28) from $136.0 million in the first quarter of 2025.
Beyond CASGEVY, the company highlighted progress across in vivo liver editing, siRNA programs, the zugo-cel autoimmune and oncology platform, in vivo CAR-T approaches, and its regenerative medicine program in diabetes, underscoring a broad pipeline alongside its first commercial product.
CRISPR Therapeutics completed a private offering of $600.0 million aggregate principal amount of convertible senior notes due 2031, generating approximately $585.2 million in net proceeds for general corporate purposes. The notes are senior unsecured obligations with an effective coupon of 1.125%, increased to 1.7308% to offset anticipated Swiss withholding tax.
Holders may convert at an initial rate of 13.0617 common shares per $1,000 principal amount, implying a conversion price of about $76.56 per share, a 45.0% premium to the $52.80 last reported sale price on the Nasdaq Global Market on March 10, 2026. Initially, a maximum of 11,363,580 common shares may be delivered upon conversion based on the initial maximum conversion rate.
The notes mature on March 1, 2031, pay interest semiannually starting September 1, 2026, and are redeemable at the company’s option on or after March 6, 2029 if share price conditions are met. They were sold in an unregistered Rule 144A private placement, and the shares issuable upon conversion are expected to be delivered in transactions exempt under Section 3(a)(9).
CRISPR Therapeutics AG is raising capital through a private offering of $550 million aggregate principal amount of convertible senior notes due 2031, sold to qualified institutional buyers. The offering was upsized from a previously proposed $350 million.
The notes carry an effective coupon of 1.125%, increased to 1.7308% to offset anticipated Swiss withholding tax, and mature on March 1, 2031 unless earlier converted, redeemed or repurchased. They are initially convertible at 13.0617 common shares per $1,000 principal amount, implying a conversion price of about $76.56 per share, a roughly 45% premium to the $52.80 share price on March 10, 2026. CRISPR Therapeutics estimates net proceeds of approximately $536.3 million, or $585.2 million if the purchasers’ option is fully exercised, and plans to use the funds for general corporate purposes.
CRISPR Therapeutics reported fourth quarter and full-year 2025 results, showing early CASGEVY commercialization alongside higher losses as it invests in its pipeline. CASGEVY generated $54 million in Q4 2025 revenue and $116 million for the full year, with 64 patients infused in 2025 and 147 initiating treatment.
Cash, cash equivalents and marketable securities were $1,975.8 million as of December 31, 2025, slightly above $1,903.8 million a year earlier. Q4 2025 R&D expense rose to $83.5 million from $71.7 million, and collaboration expense jumped to $53.7 million from $10.4 million due to the absence of a prior-year cost deferral.
Net loss widened to $130.6 million for Q4 2025 versus $37.3 million a year ago, and to $581.6 million for 2025 versus $366.3 million in 2024. The company highlighted progress across in vivo liver editing, its siRNA collaboration, autoimmune and oncology CAR-T programs, and regenerative medicine, with multiple clinical and data updates expected in 2026.
CRISPR Therapeutics AG filed an update on multiple gene-editing programs across cardiovascular, autoimmune, oncology and regenerative medicine. The company highlighted continued progress with its in vivo programs using a proprietary lipid nanoparticle delivery platform, including CTX310, which in 2025 showed deep and durable reductions in triglycerides and LDL after a single intravenous dose with a well‑tolerated safety profile and has moved into Phase 1b trials.
CTX320, targeting LPA, has shown reductions of up to 73% in a dose‑escalation trial, while next‑generation candidate CTX321 with about two‑fold greater preclinical potency is in IND/CTA‑enabling studies. Additional preclinical assets include CTX460 for alpha‑1 antitrypsin deficiency and CTX340 for refractory hypertension. Zugocabtagene geleucel (zugo‑cel) is in Phase 1 autoimmune trials where early systemic lupus erythematosus patients achieved drug‑free remission or full score improvement, and an oncology trial is ongoing alongside a new collaboration with Eli Lilly. In regenerative medicine for diabetes, CTX211 data with detectable C‑peptide at 12 months support a move to next‑generation candidate CTX213.
CRISPR Therapeutics AG furnished a Form 8‑K announcing its financial results for the quarter ended September 30, 2025. The company provided the full details in a press release attached as Exhibit 99.1 under Item 2.02.
The materials are furnished, not filed, and therefore are not subject to Section 18 liabilities or incorporated by reference except as specifically stated. The 8‑K was signed by CEO Samarth Kulkarni, Ph.D., on November 10, 2025.
CRISPR Therapeutics AG filed a prospectus supplement to offer and sell, from time to time and at its sole discretion through Jefferies as sales agent, additional common shares with an aggregate offering price of $600,000,000. The common shares will be issued under the company’s automatically effective shelf registration statement on Form S-3ASR (File No. 333-281262) filed on August 5, 2024.
The filing notes the engagement of Jefferies LLC under an existing Open Market Sale Agreement and includes a legal opinion from Walder Wyss AG as Exhibit 5.1. This action provides the company with the ability to raise capital over time via open market sales, subject to applicable securities laws.
CRISPR Therapeutics (Nasdaq: CRSP) filed an 8-K reporting new in-vivo cardiovascular data.
CTX310: Phase 1 trial shows up to 82% triglyceride and 86% LDL-C reductions at 0.8 mg/kg, with no clinically significant liver-enzyme changes.
CTX320: Phase 1 enrollment ongoing; next clinical update shifted to H1 2026 to incorporate emerging Lp(a) insights.
CTX340: IND/CTA-enabling studies progressing for refractory hypertension.
The company highlights validated surrogate endpoints, a favorable safety profile, and includes customary forward-looking statement disclaimers.